Content Detail

• Content META

  Title	iSpecimen Reports Third Quarter 2024 Results GlobeNewsWire Today at 1:00pm GMT+1
  ID	4410177
  External ID	7282164970
  Author	Unknown
  Published Date	Nov. 7, 2024, 6:10 a.m.
  Summary	LEXINGTON, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medic
  Tags	None
  URL	https://pr.greenvillebusinessmag.com/article/ispecimen-reports-third-quarter-2024-results?storyid=672caca6def489cc6dfc1489
  Sentiment	Negative: 0.01806    Neutral: 0.03743    Positive: 0.94450
  Relevance	0.02083

• Content Details

  Content ID	2627652
  Key	271c4b3a-556c-4aee-bfd8-5d062664951d
  Content	LEXINGTON, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three and nine month periods ended September 30, 2024. "The third quarter was a period of continued strategic transformation for iSpecimen, primarily driven by several key initiatives," said Tracy Curley, CEO of iSpecimen. "First, we completed a 1-for-20 reverse stock split which helped the Company maintain its Nasdaq listing. Additionally, we secured a $1,000,000 loan facility with favorable terms, an agreement which included access to an additional $1,000,000 revolving credit line tied to a future $5,000,000 financing, which we successfully completed on October 31, 2024.” "I am particularly pleased with the progress and success of our Supplier Refresh program, which is aimed at streamlining our network and focusing on our most productive relationships. In doing so, we have strategically reduced our supplier base this year by 157 suppliers to 75 key suppliers, with an additional 13 new prospects currently in our pipeline. This focused approach has significantly improved the quality and efficiency of our supplier network, while reducing administrative overhead. Combined with our Next Day Quotes program, these initiatives continue to accelerate our sales velocity and enhance conversion rates. These operational improvements, combined with our cost optimization efforts in the third quarter, which included relocating our headquarters and reducing our headcount, are expected to yield over $750,000 in annual savings. As we move closer to a cash flow neutral position we have continued our cost cutting efforts into the fourth quarter. Through November 2024, we have executed additional activities that are expected to yield an additional estimated $2,350,000 in annual savings. In aggregate, these actions provide a solid foundation from which to strengthen our position in the biospecimen industry and drive shareholder value.” Third Quarter and Nine Month 2024 Highlights Subsequent Events Financial Results for the Three and Nine Months Ended September 30, 2024 For the three months ended September 30, 2023, iSpecimen had revenue of approximately $2,660,000, compared with approximately $2,780,000 for the three months ended September 30, 2023. This result was primarily due to a 39% decrease in average selling price per specimen for the third quarter of 2024, compared with approximately $518 for the same period in 2023. The decrease in the average selling price per specimen was offset by a 58% increase in specimen count to 8,461 specimens for the three months ended September 30, 2024, compared with 5,367 specimens for the same period last year. For the nine months ended September 30, 2024, revenue increased by approximately $463,000, or 6%, to $7,820,000, from approximately $7,350,000 for the same period in 2023. This was result was primarily due to a 942, or 5%, increase in specimen count, to 19,620 specimens, compared with 18,678 specimens for same period in 2023. The average selling price per specimen also increased by approximately $4, or 1%, to $398 for the nine months ended September 30, 2024, compared with approximately $394 for the same period last year. For the three months ended September 30, 2024, cost of revenue increased by approximately $162,000 to $1,550,000, compared with approximately $1,390,000 for the same period in 2023. This result was attributable to an approximately 58% increase in the number of specimens accessioned for the three months ended September 30, 2024, compared with the same period in the prior year, offset by an approximately $76, or 29%, decrease in the average cost per specimen for the recent nine month period. For the nine month period ended September 30, 2024, cost of revenue increased by approximately $586,000 to $3,980,000, compared with approximately $3,390,000 for the same period in 2023. This result was attributable to a $21, or 12%, increase in the average cost per specimen and a 5% increase in the number of specimens accessioned, compared with the same period in the prior year. For the three month period ended September 30, 2024, general and administrative expenses decreased by approximately $209,000, or 19%, to approximately $893,000, compared with approximately $1,100,000 for same period in 2023. The decrease was attributable to decreases in compensation costs of approximately $172,000, general operating expenses of approximately $71,000, professional fees of approximately $20,000, utilities and facilities expenses of approximately $16,000, and depreciation and amortization of approximately $7,000, partially offset by increases in taxes and insurance of approximately $57,000 and bad debt expense of approximately $20,000. For the nine months ended September 30, 2024, general and administrative expenses decreased approximately $470,000, or 10%, to approximately $4,050,000 compared with approximately $4,520,000 for the nine months ended September 30, 2023. The period over period decrease was attributable to decreases in compensation costs of approximately $470,000, general operating expenses of approximately $175,000, depreciation and amortization of approximately $51,000, bad debt expense of approximately $37,000, utilities and facilities expenses of approximately $26,000, which were partially offset by increases in taxes and insurance of approximately $148,000 and professional fees of approximately $141,000. For the third quarter ended September 30, 2024, net loss was approximately $1,440,000, or $(2.10) per share, for the third quarter of 2024, compared with a net loss of approximately $2,110,000, or $(4.66) per share, for the third quarter of 2023. For the nine months ended September 30, 2024, net loss was approximately $6,450,000, or $(11.30) per share, compared with a net loss of approximately $8,030,000, or $(17.78) per share, for the first nine months of 2023. As of September 30, 2024, cash and cash equivalents, as well as available for sale securities, were approximately $1,750,000, compared with approximately $5,000,000 as of December 31, 2023. About iSpecimen iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com Forward Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," “believe," "estimate," "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. For further information, please contact: Investor Contact KCSA Strategic Communications Phil Carlson iSpecimen@kcsa.com iSpecimen Inc. Condensed Balance Sheets iSpecimen Inc. Condensed Statements of Operations and Comprehensive Loss (Unaudited)
  Content Reference URL	None

• Publisher

  Publisher Name	Greenville Business Magazine
  Publisher URL	https://pr.greenvillebusinessmag.com
  Description	None
  Trust Flow Score	0
  Citation Flow Score	26

• Data Source

  Data Source Name	Quantexa News
  Data Source Type	news
  Data Source URL	https://app.aylien.com/dashboard
  Description	Welcome to Quantexa News API — the most powerful way to aggregate, filter, and integrate global news data into your apps and models.
  Weight	10